Tags

Type your tag names separated by a space and hit enter

Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.
Clin Chem. 2013 Dec; 59(12):1770-9.CC

Abstract

BACKGROUND

Oral Δ(9)-tetrahydrocannabinol (THC) is effective for attenuating cannabis withdrawal and may benefit treatment of cannabis use disorders. Oral fluid (OF) cannabinoid testing, increasing in forensic and workplace settings, could be valuable for monitoring during cannabis treatment.

METHODS

Eleven cannabis smokers resided on a closed research unit for 51 days and received daily 0, 30, 60, and 120 mg of oral THC in divided doses for 5 days. There was a 5-puff smoked cannabis challenge on the fifth day. Each medication session was separated by 9 days of ad libitum cannabis smoking. OF was collected the evening before and throughout oral THC sessions and analyzed by 2-dimensional GC-MS for THC, cannabidiol (CBD), cannabinol (CBN), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH).

RESULTS

During all oral THC administrations, THC OF concentrations decreased to ≤ 78.2, 33.2, and 1.4 μg/L by 24, 48, and 72 h, respectively. CBN also decreased over time, with concentrations 10-fold lower than THC, with none detected beyond 69 h. CBD and 11-OH-THC were rarely detected, only within 19 and 1.6 h after smoking, respectively. THCCOOH OF concentrations were dose dependent and increased over time during 120-mg THC dosing. After cannabis smoking, THC, CBN, and THCCOOH concentrations showed a significant dose effect and decreased significantly over time.

CONCLUSIONS

Oral THC dosing significantly affected OF THCCOOH but minimally contributed to THC OF concentrations; prior ad libitum smoking was the primary source of THC, CBD, and CBN. Higher cannabinoid concentrations following active oral THC administrations vs placebo suggest a compensatory effect of THC tolerance on smoking topography.

Authors+Show Affiliations

Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD;No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Intramural

Language

eng

PubMed ID

23938457

Citation

Lee, Dayong, et al. "Oral Fluid Cannabinoids in Chronic Cannabis Smokers During Oral Δ9-tetrahydrocannabinol Therapy and Smoked Cannabis Challenge." Clinical Chemistry, vol. 59, no. 12, 2013, pp. 1770-9.
Lee D, Vandrey R, Mendu DR, et al. Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge. Clin Chem. 2013;59(12):1770-9.
Lee, D., Vandrey, R., Mendu, D. R., Anizan, S., Milman, G., Murray, J. A., Barnes, A. J., & Huestis, M. A. (2013). Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge. Clinical Chemistry, 59(12), 1770-9. https://doi.org/10.1373/clinchem.2013.207316
Lee D, et al. Oral Fluid Cannabinoids in Chronic Cannabis Smokers During Oral Δ9-tetrahydrocannabinol Therapy and Smoked Cannabis Challenge. Clin Chem. 2013;59(12):1770-9. PubMed PMID: 23938457.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge. AU - Lee,Dayong, AU - Vandrey,Ryan, AU - Mendu,Damodara R, AU - Anizan,Sebastien, AU - Milman,Garry, AU - Murray,Jeannie A, AU - Barnes,Allan J, AU - Huestis,Marilyn A, Y1 - 2013/08/12/ PY - 2013/8/14/entrez PY - 2013/8/14/pubmed PY - 2014/1/24/medline SP - 1770 EP - 9 JF - Clinical chemistry JO - Clin Chem VL - 59 IS - 12 N2 - BACKGROUND: Oral Δ(9)-tetrahydrocannabinol (THC) is effective for attenuating cannabis withdrawal and may benefit treatment of cannabis use disorders. Oral fluid (OF) cannabinoid testing, increasing in forensic and workplace settings, could be valuable for monitoring during cannabis treatment. METHODS: Eleven cannabis smokers resided on a closed research unit for 51 days and received daily 0, 30, 60, and 120 mg of oral THC in divided doses for 5 days. There was a 5-puff smoked cannabis challenge on the fifth day. Each medication session was separated by 9 days of ad libitum cannabis smoking. OF was collected the evening before and throughout oral THC sessions and analyzed by 2-dimensional GC-MS for THC, cannabidiol (CBD), cannabinol (CBN), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). RESULTS: During all oral THC administrations, THC OF concentrations decreased to ≤ 78.2, 33.2, and 1.4 μg/L by 24, 48, and 72 h, respectively. CBN also decreased over time, with concentrations 10-fold lower than THC, with none detected beyond 69 h. CBD and 11-OH-THC were rarely detected, only within 19 and 1.6 h after smoking, respectively. THCCOOH OF concentrations were dose dependent and increased over time during 120-mg THC dosing. After cannabis smoking, THC, CBN, and THCCOOH concentrations showed a significant dose effect and decreased significantly over time. CONCLUSIONS: Oral THC dosing significantly affected OF THCCOOH but minimally contributed to THC OF concentrations; prior ad libitum smoking was the primary source of THC, CBD, and CBN. Higher cannabinoid concentrations following active oral THC administrations vs placebo suggest a compensatory effect of THC tolerance on smoking topography. SN - 1530-8561 UR - https://www.unboundmedicine.com/medline/citation/23938457/Oral_fluid_cannabinoids_in_chronic_cannabis_smokers_during_oral_δ9_tetrahydrocannabinol_therapy_and_smoked_cannabis_challenge_ L2 - https://academic.oup.com/clinchem/article-lookup/doi/10.1373/clinchem.2013.207316 DB - PRIME DP - Unbound Medicine ER -